Valerio Therapeutics Is A Clinical Stage Biotechnology Company Focused On Developing Innovative Treatments For Cancer And Inflammatory Diseasesbased In France With Operations In The United Statesthe Company Was Formerly Known As Onxeo Savalerio Therapeutics Utilizes Its Platona C Platform To Create First In Class Therapies That Target Intracellular Dna Binding Functions The Company Specializes In Dna Decoy Therapeutics And Has Several Clinical Programs Underwaynotable Products Include Livataga Doxorubicin Transdrug In Phase Iii For Primary Liver Cancerand Validivea Clonidine Lauriad In Phase Ii For Severe Oral Mucositis In Head And Neck Cancer Patientsvalerio Therapeutics Also Has Registered Products Such As Beleodaqbelinostatfor Peripheral T Cell Lymphomaloramycoravigfor Oropharyngeal Candidiasisand Sitavig For Recurring Herpes Labialisadditionallythe Acquisition Of Emglev Therapeutics Has Led To The Establishment Of Valour Bioa Subsidiary Focused On Single Domain Antibody Therapeutics
No conferences found for this company.
| Company Name | Valerion Therapeutics Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
